A single-operator experience using EchoLaser SoracteLite™ for focal laser ablation of prostate cancer: One more arrow in the quiver for the conservative management of the disease

Abstract

Background: The aim of this study was to evaluate the outcomes of patients suffering prostate cancer (PCa) treated consewatively using 1064 run laser energy for focal laser ablation (FLA). The patients included in the study were unsuitable for surgery or unwilling to receive external beam radiotherapy because they were afraid of the possible side effects of whole-gland therapies. Methods: This study included patients with a diagnosis of non-metastatic PCa who underwent FLA using SoracteLite,M system. Tissue ablation was performed at a fixed power of 5 W by (he diode multichannel laser system FchoLaser X4 that uses laser light transmitted through optical fibres causing the target tissue to undergo irreversible thermal damage. Functional outcomes were evaluated with the International Prostatic Symptoms Score (IPSS) and 5-item version of the International Index of Erectile Function (UFF-5) before the treatment and one year later. Results: Ten patients suffering non-metastatic PCa were included. Four decided upon a conservative treatment because of reduced performance status and for six patients the procedure was chosen electively. All patients underwent multiparametric magnetic resonance imaging at 3 and 12 month and eight out of ten patients underwent prostate biopsy at 6 months. Persistent disease was detected in 3 patients who underwent a second ablation. In these patients at the biopsy following the second ablation none harbored residual disease. At follow-up, no patient suffered urinary incontinence requiring the use of pads. No significant worsening in sexual potency measured with IIEF-5 (p = 0.356) or prostatic symptoms measured at IPSS (p = 0.462) were recorded comparing pre-treatment condition vs one-year follow-up. Compared with baseline, prostate-specific antigen was significantly reduced at one-year follow-up (3.7 ∗ 1.1 vs 7.9 ± 4.1 ng/mL; p = 0.008). Conclusions: Although whole gland therapies remain the gold standard treatment for PCa, our results indicate that the SoracteLiteM system for focal laser ablation, as a very preliminary step, appears to offer a short-term oncologic control of PCa with negligible side effects.